Erythropoietic Protoporphyria clinical trials at UCSF

5 in progress, 1 open to eligible people

Showing trials for

  • Longitudinal Study of the Porphyrias

    open to all eligible people

    The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.

    San Francisco 5391959, California 5332921 and other locations

  • Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    Sorry, not currently recruiting here

    To evaluate the long-term safety and tolerability of oral dersimelagon.

    San Francisco 5391959, California 5332921 and other locations

  • INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

    Sorry, in progress, not accepting new patients

    To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

    San Francisco 5391959, California 5332921 and other locations

  • Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP

    Sorry, accepting new patients by invitation only

    This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

    San Francisco 5391959, California 5332921 and other locations

  • Bitopertin in Participants With EPP or XLP (APOLLO)

    Sorry, not currently recruiting here

    The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: - Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. - How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Participants will complete daily questionnaires and attend study visits for assessments.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for Erythropoietic Protoporphyria research studies include .

Last updated: